ProKidney Corp. (PROK)
| Market Cap | 554.10M |
| Revenue (ttm) | 893,000 |
| Net Income (ttm) | -68.99M |
| Shares Out | 301.96M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 263,288 |
| Open | 1.870 |
| Previous Close | 1.860 |
| Day's Range | 1.830 - 1.910 |
| 52-Week Range | 0.540 - 7.130 |
| Beta | 1.86 |
| Analysts | Strong Buy |
| Price Target | 7.40 (+303.27%) |
| Earnings Date | May 8, 2026 |
About PROK
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a... [Read more]
Financial Performance
In 2025, ProKidney's revenue was $893,000, an increase of 1075.00% compared to the previous year's $76,000. Losses were -$68.99 million, 12.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PROK stock is "Strong Buy." The 12-month stock price target is $7.4, which is an increase of 303.27% from the latest price.
News
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney dise...
ProKidney Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rilparencel, an autologous cell therapy, is advancing through a pivotal phase III trial for advanced CKD, with top-line data expected in Q2 2027. Phase II results showed significant improvement in kidney function and strong safety, while manufacturing and commercial preparations are underway.
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disea...
ProKidney Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing an autologous cell therapy for advanced CKD, with phase III trials over 50% enrolled and an accelerated approval readout expected in Q2 2027. Strong phase II data, a robust safety profile, and significant market potential support commercial prospects.
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disea...
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented...
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The conference highlighted significant progress in the Phase III program for advanced CKD, including FDA alignment on accelerated approval using eGFR slope and a robust effect size. Financially, the company is well-funded through mid-2027, with a large addressable market and strong manufacturing capabilities.
ProKidney Transcript: Citi's Biopharma Back to School Conference
Phase II data showed a significant reduction in kidney function decline with rilparencel, and detailed results will be presented at ASN Kidney Week. The phase III PROACT 1 trial is over 50% enrolled, targeting advanced CKD, with accelerated approval readout expected in Q2 2027.
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney ...
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference
A cell therapy for advanced CKD showed strong Phase II results, with a 78% improvement in eGFR decline and plans for accelerated approval based on a single Phase III trial. Manufacturing and commercial readiness are in place, with key data and regulatory updates expected in the next year.
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on Augu...
ProKidney: What's Happening With PROK Stock?
ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from chro...
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying
The stock of the day on Tuesday was ProKidney Corp.'s, as it was both the biggest gainer and the most actively traded on major U.S. exchanges, after the biotechnology company's diabetes treatment prod...
Gold Falls 1%; ProKidney Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.
Why Is Penny Stock ProKidney Trading Higher On Tuesday?
ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
WINSTON-SALEM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidn...
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
WINSTON-SALEM, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fi...